Pages that link to "Q27307459"
Jump to navigation
Jump to search
The following pages link to HMGB1 mediates endogenous TLR2 activation and brain tumor regression (Q27307459):
Displaying 50 items.
- The implication and potential applications of high-mobility group box 1 protein in breast cancer (Q26744069) (← links)
- Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases (Q26768480) (← links)
- Overview of current immunotherapeutic strategies for glioma (Q26776345) (← links)
- Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications (Q26779221) (← links)
- The role of mesenchymal stem cells in cancer development (Q26823870) (← links)
- Gene therapy for brain tumors: basic developments and clinical implementation (Q26829086) (← links)
- Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials (Q27014829) (← links)
- Are BiTEs the "missing link" in cancer therapy? (Q28083907) (← links)
- Toll-like receptor 4 enhancement of non-NMDA synaptic currents increases dentate excitability after brain injury (Q30392483) (← links)
- DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity (Q30499197) (← links)
- Alarmins: awaiting a clinical response (Q30523797) (← links)
- Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth (Q30842176) (← links)
- Blocking TLR2 activity attenuates pulmonary metastases of tumor (Q33490618) (← links)
- Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression (Q33551268) (← links)
- Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM (Q33578030) (← links)
- Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy (Q33603599) (← links)
- Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial (Q33605719) (← links)
- High-mobility group box 1 and cancer (Q33638306) (← links)
- Toll-like receptor 2 and facial motoneuron survival after facial nerve axotomy (Q33673185) (← links)
- Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. (Q33740759) (← links)
- Single vs. combination immunotherapeutic strategies for glioma. (Q33746041) (← links)
- Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? (Q33828102) (← links)
- Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. (Q33828114) (← links)
- A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics (Q33877450) (← links)
- Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines. (Q33908539) (← links)
- EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model (Q33924763) (← links)
- Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors (Q33950709) (← links)
- TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. (Q34000194) (← links)
- Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma (Q34012284) (← links)
- Adenoviral vector-mediated gene therapy for gliomas: coming of age. (Q34022048) (← links)
- Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology (Q34069598) (← links)
- Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. (Q34116278) (← links)
- Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma (Q34208293) (← links)
- Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway (Q34227734) (← links)
- Toll-like receptors and cancer, particularly oral squamous cell carcinoma. (Q34239239) (← links)
- Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity (Q34287535) (← links)
- Human herpesvirus 6 latent infection in patients with glioma (Q34298606) (← links)
- Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. (Q34359268) (← links)
- RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells (Q34486464) (← links)
- HMGB1 in health and disease (Q34622835) (← links)
- Blocking TLR2in vivoProtects against Accumulation of Inflammatory Cells and Neuronal Injury in Experimental Stroke (Q34627666) (← links)
- Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. (Q34647123) (← links)
- Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma (Q34657329) (← links)
- Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion. (Q34775318) (← links)
- Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling (Q34886935) (← links)
- High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus. (Q34953262) (← links)
- Temporal and spatial patterns of endogenous danger signal expression after wound healing and in response to lymphedema (Q34979277) (← links)
- Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity (Q35059053) (← links)
- Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier! (Q35089270) (← links)
- Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer (Q35155622) (← links)